A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Condition: PARP Inhibitor for Esophageal Squamous Cell Carcinoma Intervention: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsor: Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Conditions: PARP Inhibitor for Esophageal Squamous Cell Carcinoma Interventions: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsors: Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials
A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors
Condition: Solid Tumor Interventions: Drug: QLS31905; Drug: Nab paclitaxel; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Cisplatin Sponsor: Qilu Pharmaceutical Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 18, 2023 Category: Research Source Type: clinical trials
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
Conditions: Biliary Tract Cancer; Cholangiocarcinoma Interventions: Drug: Gemcitabine; Drug: Nab paclitaxel; Drug: Cisplatin; Procedure: Curative Surgery; Drug: Capecitabine Sponsor: Gruppo Oncologico del Nord-Ovest Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 14, 2023 Category: Research Source Type: clinical trials
